Nausea and vomiting in pregnancy therapy reference (2026)

Nausea and vomiting in pregnancy therapy in 2026 organises by severity.

For mild to moderate morning sickness: lifestyle measures (small frequent meals, avoiding triggers, ginger), pyridoxine (vitamin B6), and pyridoxine plus doxylamine combination (the modern first-line pharmacotherapy).

For moderate persistent nausea and vomiting not responding to first-line: ondansetron (widely used and generally considered safe in pregnancy based on accumulated evidence; a small first-trimester cardiac association has been described and is part of risk-benefit discussion), metoclopramide, prochlorperazine, promethazine.

For hyperemesis gravidarum (severe nausea and vomiting with weight loss, dehydration, and electrolyte disturbance): hospitalisation for severe cases for IV fluid replacement, antiemetic therapy. Structured outpatient hydration and antiemetic infusion pathways are increasingly available and reduce hospitalisation. Combined antiemetic therapy with multiple agents is often needed. Corticosteroids in selected refractory cases. Nasoenteric or parenteral nutrition in severe cases.

The biology behind the new direction. GDF15 (growth differentiation factor 15) has emerged as a major mechanistic driver of pregnancy-related nausea and vomiting; women with hyperemesis gravidarum have higher GDF15 levels and altered GDF15 sensitivity. GDF15-targeted programs are entering early clinical development with the proposition of mechanism-targeted therapy for hyperemesis gravidarum.

The care-pathway question matters. Hyperemesis gravidarum is associated with substantial maternal morbidity (electrolyte disturbance, weight loss, mental health impact, sometimes job loss and family disruption) and is often inadequately recognised. Integrated obstetric-and-mental-health care models, structured outpatient pathways, and patient-centred discussion of the spectrum of severity are part of comprehensive modern care.